Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewTreatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceKASL clinical practice guidelines: management of hepatitis CResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsDaclatasvir: potential role in hepatitis CState of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationHCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, BrazilRapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader AssayGenetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European DatabankHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsUltradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.Hepatitis C virus NS5A inhibitors and drug resistance mutations.A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors.Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/RibavirinPrevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus.Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in JapanEfficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infectionPrediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.Interferon-free hepatitis C therapy: how close are we?What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?Novel therapeutic approaches for hepatitis C.Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.Advances in newly developing therapy for chronic hepatitis C virus infection.Efficacy of daclatasvir in hepatitis C virus.Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation; a Japanese multicenter experience."Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline.The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
P2860
Q24628717-8B525F92-3B05-4496-B635-9ECE7CF1E36FQ26740219-0C96942A-74BD-4F81-B193-5454D30E12F6Q26752471-CCDFF93A-A17F-4209-9EAE-A6A0AD85698FQ26777408-863319A2-E8F1-4017-839B-CF65056C4154Q27012741-6D894B91-DB09-4EAE-97B4-275FE5B51006Q28079102-38A77E65-0580-483F-8933-08999D942BE8Q28538943-B24AF496-B3DD-48C3-ADA9-7FF5DB5B38B3Q28548426-E6E160DC-F85B-42DC-83F6-E6259091F8E3Q28553430-0C078F99-0873-45C5-9D16-CD0D97E3872CQ28652352-37C8FEF8-4590-415A-9298-04F094805D2FQ33622970-28BBE7FD-ACA7-4C07-8797-EF0988DDEDF8Q34411617-16E28FE9-342C-44B3-A190-A67B8BED40A4Q34513827-B714E582-9788-43C6-883B-5B69F029FA13Q34802167-3E83A6C2-7B2D-4944-8CB2-4DEB84F92EF1Q35735285-17D6DCBE-F8CB-413A-9EED-FB8C6CD15008Q35759025-D07B9DCB-495F-4185-B423-C84A0ADFD41DQ35905985-3027121A-8184-4871-B489-3C9613F49F16Q36687938-289022EE-6E1E-444E-B60C-BC21DA22ED08Q36970046-1F0A32FB-B85D-496F-A745-C6D417C059AFQ37097611-96DF4329-0E85-469F-9DCE-2D7422E01DFEQ37125066-750440BA-63EA-46AD-8559-5921AD30120DQ37310564-E8A14500-B794-478D-970F-87BFBF785148Q37373261-3777D59B-DED9-443D-A2E2-B74D4C34CAD6Q37426527-2C2959D8-FD9D-4CFB-AF18-A927973DC611Q37546699-0994510E-5C27-4039-BED7-CDD40EEE5C30Q38039192-6AA33E97-D70F-4C25-A651-14C89A65B1DAQ38068357-8FAFB25D-37AE-48A9-9863-99438887FF52Q38152674-5EF57A1A-27F4-4715-9A80-BAF020543A86Q38156875-AA791458-C7E3-445E-ACEA-54D98F93B11CQ38215652-A73EA5E7-CF07-48C5-94CF-E33135BC36A7Q38233602-81BAC4C1-84DC-4A5A-9559-0D0CC3ACD997Q38249065-FB579371-2213-4AF3-88AB-7E48AA563A93Q38611842-25ED6CD1-4FFE-4F8B-B485-8435A86726B7Q38735359-6FFD669D-0130-4D78-BE0A-772A75126E08Q38779980-0C02A593-377A-47AD-8B13-34B303339BF7Q39034453-7BCB1F53-C3E1-499C-B87E-65298D9A843CQ40053650-821A3353-889E-4253-B910-508A00B2A831Q40317327-79BA5AC6-C4F6-4BCD-B054-D8C9ACBF9560Q40340001-0EA8C11E-7EBA-4E10-895D-330343BF9B1BQ40375437-F6FA7625-53AD-4D7F-A26C-2150C96B0812
P2860
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prevalence of hepatitis C viru ...... tis patients with genotype 1b.
@ast
Prevalence of hepatitis C viru ...... tis patients with genotype 1b.
@en
Prevalence of hepatitis C viru ...... hibitors or the NS5A inhibitor
@nl
type
label
Prevalence of hepatitis C viru ...... tis patients with genotype 1b.
@ast
Prevalence of hepatitis C viru ...... tis patients with genotype 1b.
@en
Prevalence of hepatitis C viru ...... hibitors or the NS5A inhibitor
@nl
prefLabel
Prevalence of hepatitis C viru ...... tis patients with genotype 1b.
@ast
Prevalence of hepatitis C viru ...... tis patients with genotype 1b.
@en
Prevalence of hepatitis C viru ...... hibitors or the NS5A inhibitor
@nl
P2093
P1476
Prevalence of hepatitis C viru ...... itis patients with genotype 1b
@en
P2093
Fumitaka Suzuki
Hiromitsu Kumada
Hitomi Sezaki
Kenji Ikeda
Mariko Kobayashi
Masahiro Kobayashi
Norio Akuta
Rie Mineta
Sachiyo Watahiki
Satoshi Saito
P304
P356
10.1016/J.JCV.2012.04.024
P577
2012-06-01T00:00:00Z